These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37624625)

  • 41. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, April-June 2021.
    Am J Health Syst Pharm; 2021 Sep; 78(19):e9-e10. PubMed ID: 34392350
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Boxed warnings and other FDA communication tools.
    Marks NS; Weiss K
    Am Fam Physician; 2010 Feb; 81(3):259. PubMed ID: 20112882
    [No Abstract]   [Full Text] [Related]  

  • 45. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling.
    Shulman LP; Bateman LH; Creinin MD; Cullins VE; Doyle LL; Godfrey E; Murphy P; Rodriguez P; Spear SJ; Stewart FH; Thomas MA; Westhoff CL; Worthington S
    Contraception; 2006 May; 73(5):440-2. PubMed ID: 16627028
    [No Abstract]   [Full Text] [Related]  

  • 46. Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings Highlights.
    Rose B
    Hosp Pharm; 2016 Jun; 51(6):491-2. PubMed ID: 27354752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA Boxed Warning for Immediate-Release Opioids.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coverage of FDA medication boxed warnings in commonly used drug information resources.
    Cheng CM; Guglielmo BJ; Maselli J; Auerbach AD
    Arch Intern Med; 2010 May; 170(9):831-3. PubMed ID: 20458094
    [No Abstract]   [Full Text] [Related]  

  • 50. US Food and Drug Administration Black Box Warnings.
    Smith RG
    J Am Podiatr Med Assoc; 2020 Jan; 110(1):Article10. PubMed ID: 32073327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Summaries of safety labeling changes approved by FDA-boxed warnings highlights March-June 2016.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Sep; 73(17):e573-8. PubMed ID: 27543581
    [No Abstract]   [Full Text] [Related]  

  • 52. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, March-June 2020.
    Am J Health Syst Pharm; 2020 Sep; 77(19):e11-e12. PubMed ID: 34279587
    [No Abstract]   [Full Text] [Related]  

  • 53. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, March-June 2020.
    Am J Health Syst Pharm; 2020 Sep; 77(19):1542. PubMed ID: 34279586
    [No Abstract]   [Full Text] [Related]  

  • 54. Warnings for health care products: a communication perspective.
    Mundt J; Driver RW
    Health Mark Q; 1994; 12(2):55-75. PubMed ID: 10141085
    [No Abstract]   [Full Text] [Related]  

  • 55. Bringing greater transparency to "black box" warnings.
    Buckley NA; Rossi S
    Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
    Willy ME; Li Z
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
    Cowart K; Worley M; Rouby NE; Sando K
    Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.